Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. is reported to have completed the acquisition of Kashiv BioSciences, LLC, with consideration that included both cash and stock. A reporting person, Chirag Patel, filed an amended beneficial ownership statement reflecting his updated holdings and the shares he received in connection with this transaction.

Under a Membership Interest Purchase Agreement, Amneal’s subsidiary agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to adjustments, and Amneal agreed to issue an aggregate of 28,942,098 shares of Class A Common Stock to those sellers. Chirag Patel is reported to beneficially own 29,097,645 shares of Class A Common Stock, representing 8.4% of the class, based on 377,238,115 shares outstanding after including the Kashiv-related issuance. His holdings include directly owned shares, stock options, and shares held through trusts and entities CKR Investments, LLC and Shivkan Dynasty, LLC, over which he is described as having sole voting and dispositive power.

Key Figures

Cash consideration for Kashiv acquisition: $375,000,000 Shares issued in Kashiv acquisition: 28,942,098 shares Chirag Patel beneficial ownership: 29,097,645 shares +5 more

8 metrics

Cash consideration for Kashiv acquisition $375,000,000 Aggregate cash payable to Kashiv sellers under the Membership Interest Purchase Agreement

Shares issued in Kashiv acquisition 28,942,098 shares Aggregate Class A Common Stock issued to Kashiv sellers at closing

Chirag Patel beneficial ownership 29,097,645 shares Total Amneal Class A shares beneficially owned as of August 10, 2026

Ownership percentage 8.4% Percent of Amneal Class A Common Stock beneficially owned by Chirag Patel

Shares outstanding baseline 348,296,017 shares Amneal Class A Common Stock outstanding as of August 10, 2026 before Kashiv issuance

Adjusted shares outstanding 377,238,115 shares Baseline outstanding plus 28,942,098 shares issued in Kashiv acquisition

Option strike price 1 $15.01 per share 24,977 options expiring May 7, 2028

Option strike price 2 $14.05 per share 28,044 options expiring May 6, 2029

Key Terms

Schedule 13D, Membership Interest Purchase Agreement, beneficially owned, sole voting power, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 7 to (this "Amendment No. 7") amends and supplements the filed with the SEC on July 9, 2018 (the "Initial 13D""

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Membership Interest Purchase Agreement financial

"entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC"

A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.

beneficially owned financial

"the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote - 29,097,645"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition - 29,097,645"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

purchase price adjustments financial

"an aggregate amount of $375,000,000 in cash, subject to certain purchase price adjustments"

Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 06:04 PM Accepted by SEC EDGAR 08/12/2026 - 06:04 PM Learn about SEC filing dates

FAQ

What ownership stake in Amneal Pharmaceuticals (AMRX) does Chirag Patel report in this Schedule 13D/A?

Chirag Patel reports beneficial ownership of 29,097,645 shares of Amneal Class A Common Stock, representing 8.4% of the outstanding class, based on 377,238,115 shares outstanding after giving effect to shares issued in the Kashiv BioSciences acquisition.

How many Amneal (AMRX) shares were issued in the Kashiv BioSciences acquisition?

In the Kashiv BioSciences transaction, Amneal agreed to issue an aggregate of 28,942,098 shares of Class A Common Stock to the sellers, including entities associated with Chirag Patel, in addition to a substantial cash component described in the same agreement.

What cash consideration did Amneal (AMRX) agree to pay for the Kashiv acquisition?

Amneal’s subsidiary agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to purchase price adjustments, alongside the issuance of Amneal Class A Common Stock as consideration for 100% of Kashiv’s membership interests.

Which Amneal (AMRX) securities does Chirag Patel directly own or control?

Chirag Patel directly owns 1,393,470 shares of Class A Common Stock and options for 24,977 shares at $15.01 expiring May 7, 2028, and 28,044 shares at $14.05 expiring May 6, 2029, plus additional shares through trusts and affiliated LLCs.

How many Amneal (AMRX) shares are attributed to CKR and Shivkan in this filing?

In connection with the Kashiv acquisition, CKR Investments, LLC was issued 3,573,771 shares and Shivkan Dynasty, LLC was issued 2,807,963 shares of Amneal Class A Common Stock, both entities having Chirag Patel as their sole manager.

What voting and dispositive powers over Amneal (AMRX) shares does Chirag Patel report?

Chirag Patel reports sole voting power and sole dispositive power over 29,097,645 shares of Amneal Class A Common Stock, with no shared voting or dispositive power indicated for these securities in the beneficial ownership table.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

Amneal Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

03168L105

(CUSIP Number)

Christine Krentz
4 Gatehall Drive,
Parsippany, NJ, 07054
(908) 409-6700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/10/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 03168L105

1

Name of reporting person

Chirag Patel

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 29,097,645.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 29,097,645.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

29,097,645.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition (as defined below), as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.01
(b)	Name of Issuer: Amneal Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER, NEW JERSEY , 08807.
Item 3.	Source and Amount of Funds or Other Consideration
	The disclosure in Item 3 is hereby amended and supplemented by adding the following: On April 21, 2026, CKR Investments, LLC, a Delaware limited liability company ("CKR") the sole manager of which is the Reporting Person, and Shivkan Dynasty, LLC, a Delaware limited liability company ("Shivkan") the sole manager of which is the Reporting Person, entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC (the "Seller Representative") and the equityholders of Kashiv named therein, including CKR and Shivkan (the "Sellers"). On August 10, 2026, pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Amneal LLC'), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller Representative, purchased from the Sellers, including CKR and Shivkan, and the Sellers, including CKR and Shivkan sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the "Kashiv Acquisition"). Pursuant to the Purchase Agreement, at the closing of the Kashiv Acquisition, (i) Amneal LLC was required to pay to the Sellers, including CKR and Shivkan, an aggregate amount of $375,000,000 in cash, subject to certain purchase price adjustments, and (ii) Amneal was required to issue to the Sellers, including CKR and Shivkan, an aggregate of 28,942,098 shares of Class A Common Stock. CKR was issued 3,573,771 shares of Class A Common Stock, and Shivkan was issued 2,807,963 shares of Class A Common Stock, in connection with the Kashiv Acquisition.
Item 4.	Purpose of Transaction
	This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition, as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026:
(b)	Reporting Person - Chirag Patel Amount beneficially owned - 29,097,645 Percent of class - 8.4 Sole power to vote or to direct the vote - 29,097,645 Shared power to vote or to direct the vote - 0 Sole power to dispose or to direct the disposition - 29,097,645 Shared power to dispose or to direct the disposition - 0 The Reporting Person owns directly (i) 1,393,470 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028 and (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and may be deemed to beneficially own 21,269,420 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person, 3,573,771 shares of Class A Common Stock held of record by CKR, and 2,807,963 shares of Class A Common Stock held by Shivkan.
(c)	The information set forth in Item 3 of this Amendment No. 7 is incorporated by reference herein
(d)	None.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chirag Patel

Signature:	/s/ Chirag Patel
Name/Title:	Chirag Patel
Date:	08/12/2026